SOURCE: Goldman Small Cap Research, Inc.

August 12, 2013 09:02 ET

Is a Breast Cancer Treatment a Sleeper Blockbuster for Nuvilex?

BALTIMORE, MD--(Marketwired - Aug 12, 2013) - In a newly released research update, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that based on its highly successful animal trials to treat mammary tumors, a treatment for breast cancer may emerge as a real blockbuster for Nuvilex, Inc. (OTCQB: NVLX).

Despite its highly publicized successful pancreatic cancer trials, it is just reasonable to assume that if Nuvilex is able to move a human trial for breast cancer forward, there is a strong likelihood that given its profile, this treatment would be afforded an even higher valuation than the pancreatic cancer therapy. 

Prevention and treatment of breast cancer that is diagnosed in 200,000 women and kills over 40,000 in the U.S. alone each year is now a multi-billion dollar industry unto itself, highlighted by mammograms, other tests, involvement of multiple non-profit organizations, etc. Moreover, breast cancer appears to be affecting younger and younger women each year. As a result, when firms gain even modest success in their quest for ever more effective treatment for breast cancer, their stocks enjoy huge gains.

For example, Synta Pharmaceuticals recently announced early and favorable results from a Phase II clinical trial. Specifically, the Company announced preliminary treatment results from just 15 patients as compared with the expected 70 patients to be enrolled in the trial. Although management may have jumped the gun, the Street ate it up. Synta's shares rose 40% for the day, which is equivalent to $140M worth of market value. If Synta's preliminary and incomplete Phase II breast cancer results are worth a $140M jump, what is the value of Nuvilex's completed Phase II pancreatic cancer trials? More important, as Nuvilex moves ahead, and is able to post strong results for human breast cancer trials, would it also be worth over $100M in market cap? On an equal playing field, it would appear likely to even the casual observer.

It should be noted that results of the aforementioned Nuvilex Phase I/II clinical trial involving dogs with spontaneously-occurring mammary tumors were remarkably similar to its well-known human Phase II pancreatic cancer trial. Therefore, it is evident that the results of this animal trial could lead to a future successful human breast cancer clinical trial that utilizes the Company's live-cell encapsulation platform. Such success would likely result in positive share gains rivaling that of Synta and other firms focused on treating breast cancer, providing the Company and its shareholders with the makings of a real blockbuster.

To view Nuvilex reports and articles or to download the report in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit:

Contact Information